000303395 001__ 303395
000303395 005__ 20251012023045.0
000303395 0247_ $$2doi$$a10.2337/db24-0502
000303395 0247_ $$2pmid$$apmid:40762619
000303395 0247_ $$2ISSN$$a0012-1797
000303395 0247_ $$2ISSN$$a1939-327X
000303395 0247_ $$2altmetric$$aaltmetric:180423751
000303395 037__ $$aDKFZ-2025-01635
000303395 041__ $$aEnglish
000303395 082__ $$a610
000303395 1001_ $$aHarrison, Luke$$b0
000303395 245__ $$aLow-to-Moderate Dosed Cranial Irradiation in Young Mice Induces Sex-Specific Metabolic Disturbances Later in Life.
000303395 260__ $$aAlexandria, Va$$bAssoc.$$c2025
000303395 3367_ $$2DRIVER$$aarticle
000303395 3367_ $$2DataCite$$aOutput Types/Journal article
000303395 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759827226_6325
000303395 3367_ $$2BibTeX$$aARTICLE
000303395 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303395 3367_ $$00$$2EndNote$$aJournal Article
000303395 500__ $$a2025;74(10):1775–1786 / Combs
000303395 520__ $$aSurvivors of childhood cancers who received high doses (40-60 Gy) of cranial irradiation (CI) have increased risks of developing obesity, type 2 diabetes, and metabolic syndrome (MetS). Here, we subjected mice to CI of 0, 0.5, or 2 Gy directed to the hypothalamus to explore the effects of low-to-moderate doses of CI on MetS risks. Despite targeting the hypothalamus as a major metabolic control center, we did not detect hypothalamic astrocyte or microglia activation at 2 or 7 days, or at 3 months post-CI. Indirect calorimetry at 2 months post-CI showed no metabolic alterations between groups, yet female mice subjected to CI were unresponsive to leptin compared with sham. Follow-up monitoring over 2 years revealed accelerated weight gain in the 2-Gy female group and glucose intolerance in both sexes following CI. Insulin sensitivity, plasma insulin, and triglycerides remained unaltered, but both male and female 2-Gy groups showed elevated VLDL and lowered HDL cholesterol levels and aberrant hypothalamic mRNA levels of genes involved in synaptic and neuronal function, neuroinflammation, and endoplasmic reticulum stress. Mortality remained unaffected by all doses of CI. These data strongly suggest a significant risk for developing MetS following low-to-moderate doses of CI, and they support tailored clinical risk assessment and monitoring strategies for patients undergoing CI, especially when the hypothalamus is included.High-dose cranial irradiation (CI) during early developmental stages has been linked to metabolic abnormalities in later life, but causal evidence at low-to-moderate doses has been elusive. Monitoring mice for 2 years post-2-Gy CI to the hypothalamus, we found increased risks of leptin resistance, dyslipidemia, glucose intolerance, and weight gain, identifying the hypothalamus as the likely responsible region. Our findings suggest that low-to-moderate doses of CI may be a risk factor for developing metabolic syndrome. Future clinical risk assessment and monitoring strategies are needed for patients undergoing CI of hypothalamic centers governing glucose and energy metabolism.
000303395 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000303395 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303395 7001_ $$aSchriever, Sonja C$$b1
000303395 7001_ $$aBernecker, Miriam$$b2
000303395 7001_ $$aMallet, Noemi$$b3
000303395 7001_ $$aMencias Castillejo, Cristina$$b4
000303395 7001_ $$aAmeli, Hamid$$b5
000303395 7001_ $$aBaumann, Peter$$b6
000303395 7001_ $$aContreras, Raian E$$b7
000303395 7001_ $$aStolz, Jessica$$b8
000303395 7001_ $$aLindner, Rainer$$b9
000303395 7001_ $$aBartzsch, Stefan$$b10
000303395 7001_ $$aSchmid, Thomas E$$b11
000303395 7001_ $$0P:(DE-HGF)0$$aCombs, Stephanie E$$b12
000303395 7001_ $$aRosemann, Michael$$b13
000303395 7001_ $$00000-0002-8118-7588$$aPfluger, Paul T$$b14
000303395 773__ $$0PERI:(DE-600)1501252-9$$a10.2337/db24-0502$$gp. db240502$$n10$$p1775–1786$$tDiabetes$$v74$$x0012-1797$$y2025
000303395 909CO $$ooai:inrepo02.dkfz.de:303395$$pVDB
000303395 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000303395 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000303395 9141_ $$y2025
000303395 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIABETES : 2022$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-01
000303395 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bDIABETES : 2022$$d2025-01-01
000303395 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000303395 980__ $$ajournal
000303395 980__ $$aVDB
000303395 980__ $$aI:(DE-He78)MU01-20160331
000303395 980__ $$aUNRESTRICTED